TCF7 and cancer: PGE2 may therefore affect the response of TILs to IL-2, which is a notable finding given the current development of new classes of IL-2 receptor (IL-2R) agonists for cancer therapy and the emerging role of IL-2 signalling for productive anticancer responses by TCF1+ TILs33,34.